Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative medicines and generate revenue from multiple partnership deals. Exosomes are seen by the Biopharma industry as a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins – part of the global market for drug delivery systems which is growing at a compound annual growth rate (CAGR) of 5% and valued at around US$170 billion in 2021.For some medicines, exosomes are an alternative and superior means for delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell penetrating peptides, viral vectors and liposomes.Exopharm's LEAP technology solves the challenge of purifying clinical-grade exosomes at large scale and low cost. Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types. Exopharm uses variations and combinations of LOAD and EVPS to enable its Biopharma partners to improve delivery of their drug candidates and help them design and test new exosome medicines aimed at treating a wide scope of medical problems including neurological disease, infectious disease, cancer, and fibrosis.

Website: exopharm.com

Employees: 50 - 99

HQ: N/A

Location: Melbourne, VIC, AU

Revenue: 5 - 10 Million

Exopharm Ltd is a clinical-stage biopharmaceutical company based in Melbourne, Australia. The company is focused on harnessing the power of exosomes to deliver a new class of transformative medicines. Exosomes are small, membrane-bound vesicles that can be used to deliver a variety of payloads, including mRNA and proteins, to specific cells or tissues in the body. Exopharm's proprietary LEAP technology allows for the large-scale, low-cost purification of clinical-grade exosomes, and the company has also developed two exclusive technologies, LOAD and EVPS, that enable the customization of exosomes for improved delivery of drug candidates. Exopharm's technology has the potential to revolutionize the drug delivery industry, which is growing at a compound annual growth rate of 5% and valued at around US$170 billion in 2021. The company's focus on exosomes as a delivery platform offers a unique alternative to traditional drug delivery methods, such as lipid nanoparticles, cell penetrating peptides, viral vectors, and liposomes. With its cutting-edge technology and strong leadership team, Exopharm is well-positioned to make a significant impact in the biopharmaceutical industry.

Exopharm is a company that is working on a new way to deliver medicine to people's bodies. They are using something called exosomes, which are like tiny little packages that can carry medicine inside the body. The company has found a way to make sure the exosomes are pure and can be made in large quantities, which is important for using them in medicine. They also have two special technologies that help the exosomes deliver the medicine to the right cells in the body. Exopharm is working with other companies to use their technology to make new medicines that can treat a wide range of diseases, including cancer, fibrosis, infectious diseases, and neurological diseases.